ArticleDiagnostics (Basel, Switzerland)2023
Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease.
Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Association and Prevalence of Lower Urinary Tract Symptoms in Individuals with Sarcopenia: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Magnetic Resonance Imaging-Based Psoas Muscle Volume as an Additional Risk Factor for Fontan Failure: A Prospective Cohort Study.Journal of the American Heart Association · 2026Article
- Psoas muscle volume as a diagnostic indicator for sarcopenia: criteria development and comparison with traditional diagnostic approaches.Aging clinical and experimental research · 2026Article
- Imaging-based prognostic factors in patients undergoing thermal ablation for colorectal liver metastases. A retrospective study on the role of sarcopenia parameters and tumor burden score.Radiology and oncology · 2026Article
- Review
- Quantitative Assessment of Body Composition in Cirrhosis.Diagnostics (Basel, Switzerland) · 2024Review
- Three-dimensional numerical schemes for the segmentation of the psoas muscle in X-ray computed tomography images.BMC medical imaging · 2024Article
- Use of 3D-CT-derived psoas major muscle volume in defining sarcopenia in colorectal cancer.BMC cancer · 2024Article
- Article
- Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis.Scientific reports · 2024Article
- The Impact of Sarcopenia in the Long-Term Survival of Patients following Complex Endovascular Aortic Surgery for Thoracoabdominal Aortic Aneurysms.Diagnostics (Basel, Switzerland) · 2024Article
- Preoperative Body Composition Correlates with Postoperative Muscle Volume and Degeneration after Total Hip Arthroplasty.Nutrients · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Computed tomography (CT) is often used in the diagnosis of sarcopenia. In this study, we validated the assessment of sarcopenia by the psoas muscle volume using versatile software. The study involved a retrospective analysis of data from 190 patients with liver disease who underwent grip-strength testing and abdominal pelvic computed tomography. To assess sarcopenia, SYNAPSE 3D was used to obtain the skeletal muscle index, the psoas muscle index (PMI), and the simple method. We also used the recently proposed PMI cutoff values, for which the usefulness has been evaluated (O-PMI). The cutoff value of the psoas muscle volume index (PMVI) was determined using one of the diagnostic methods as the gold standard. All diagnostic methods showed that patients with sarcopenia had shorter survival, with O-PMI having the highest hazard ratio (HR) (HR, 6.12; 95% confidence interval [CI], 2.6-14.41;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.